Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dog epilepsy research is 'below par'
chocolate labrador
Epilepsy is the most common chronic neurological condition found in both dogs and people.
RVC carries out the first ever systematic review of AED efficacy

Research on the efficacy of canine epilepsy drugs is well below the expected standard, according to a new study by the Royal Veterinary College (RVC).

The first ever systematic review of canine anti-epilepsy drugs (AEDs) revealed that much of the evidence for medical treatment of the condition was based on "subpar testing".

Researchers from the RVC's canine epilepsy clinic reviewed all data published in peer-reviewed journals and publications, and assessed its reliability. According to their findings, only a few of the studies were relatively unbiased and objective.

To evaluate the reliability of the data, RVC researchers explored the evidence quality, study design, study group size, subject enrolment quality and bias risk.

Dr Dave Brodbelt, senior lecturer in companion animal epidemiology, said: "This systematic review revealed that, in veterinary medicine, the quality of evidence provided by the studies for AEDs' efficacy is not yet at a recommended standard.

"Many studies revealed a potential efficacy of a drug, but then there was a lack of follow-up studies of higher quality confirming the initial positive results."

Epilepsy affects 50,000 dogs and 600,000 people in the UK, making it the most common chronic neurological condition found in both dogs and people.

Professor Holger Volk, clinical director of the RVC Small Animal Referral Hospital, said: "Canine epilepsy is a complex condition and can be very distressing for the dog and their owners, therefore it is immensely important the drug treatments we give to our pets have been properly tested in reliable studies."

In light of the findings, RVC researchers recommend veterinary scientists work together more closely to improve the quality of testing. It is also suggested that scientists forge closer relationships with major stakeholders and funders to reduce the risk of bias.

Veterinary medicine should also take its lead from human epilepsy research, using examples such as the International League Against Epilepsy, which works to advance and distribute knowledge about epilepsy, promote research and education and improve the care available to patients.

To view the RVC's systematic review, published in BMC Veterinary Research Journal, visit:
http://www.biomedcentral.com/1746-6148/10/257/abstract

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.